1. A next-generation live-attenuated yellow fever vaccine (vYF) demonstrated noninferior immunogenicity in contrast to the standard vaccine, with almost common seroconversion by one month after vaccination.
2. Safety profiles had been related between teams, with no vaccine-related critical adversarial occasions noticed over one 12 months of follow-up.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Yellow fever stays a significant world well being menace, significantly in endemic areas of Africa and South America, the place outbreaks proceed to trigger substantial mortality and pressure vaccine provide chains. Existing vaccines are extremely efficient, however shortages throughout outbreaks have highlighted the necessity for scalable options. This randomized managed trial evaluated a next-generation vaccine (vYF) designed to enhance manufacturing capability whereas sustaining efficacy. The research discovered that vYF elicited an immune response comparable to the at the moment licensed vaccine, with almost all contributors attaining protecting antibody ranges throughout the first month. These responses continued by way of one 12 months, suggesting sturdy immunity. Importantly, the security profile of vYF carefully mirrored that of the standard vaccine, with largely delicate, transient adversarial results and no main security considerations recognized. Strengths of the research included its randomized, observer-blinded design and its use of an lively comparator which enhanced inside validity. One limitation was the restriction of enrollment to wholesome adults in a non-endemic setting, which can restrict generalizability to higher-risk populations corresponding to kids, older adults, or immunocompromised people. Additionally, the research was not powered to detect uncommon adversarial occasions, and follow-up stays ongoing for long-term sturdiness. Nonetheless, this research suggests promising early efficacy and security of a next-generation live-attenuated yellow fever vaccine.
Click to read the study in NEJM
Relevant Reading: Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models
In-Depth [randomized controlled trial]: This section 2, observer-blinded randomized managed trial evaluated the immunogenicity and security of a next-generation live-attenuated yellow fever vaccine (vYF) in contrast with the licensed vaccine (YF-VAX). A complete of 568 wholesome adults aged 18 to 60 years had been enrolled throughout 11 facilities within the United States and randomized in a 2:1 ratio to obtain a single dose of vYF or YF-VAX. The major endpoint was seroconversion at day 29 amongst contributors with no prior yellow fever an infection or vaccination within the per-protocol inhabitants. Seroconversion occurred in 328 of 329 contributors (99.7%) within the vYF group and 155 of 156 contributors (99.4%) within the YF-VAX group, yielding a between-group distinction of 0.3 share factors (95% confidence interval [CI], -1.2 to 3.2). Neutralizing antibody geometric imply titers rose considerably by day 29 in each teams, peaking at roughly 1:2654 for vYF and 1:3147 for YF-VAX in contributors with out prior publicity and remaining above the protecting threshold (≥1:10) in additional than 97% of each teams at 1 12 months. In a subgroup evaluated at day 11, protecting titers had been noticed in a smaller share of vYF recipients versus YF-VAX recipients (38% versus 61%); nevertheless, the research was not powered to assess noninferiority at this early time level. Solicited adversarial occasions occurred in 56.7% of contributors receiving vYF and 61.1% receiving YF-VAX, mostly headache (36.5% vs. 37.8%) and injection-site ache (28.7% vs. 31.4%). Serious adversarial occasions had been uncommon and never thought of associated to vaccination. These findings exhibit acceptable early efficacy and security of a next-generation yellow fever vaccine.
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works could also be reproduced with out expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article needs to be construed as medical recommendation and isn’t supposed as such by the authors or by 2 Minute Medicine, Inc.
